Genesis Therapeutics has raised $4.1M in seed funding led by Andreessen Horowitz.Read more →
Unifying AI and Biotech
We're pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines.
Learn More →
Technology
Our academia-leading research was the initial component of our expanding portfolio of AI technologies. We're combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in molecular generation and property prediction.
1
Our AI platform expands on the initial discoveries in PotentialNet — field-leading, peer-reviewed methods for molecular property prediction that co-founder Evan Feinberg invented in Stanford's acclaimed Pande lab.
Key components of our platform have been rigorously tested against current state-of-the-art methods in a collaboration between Stanford and a top-five pharma company. We achieved a step-change improvement predicting 20+ different ADMET properties.
Company
We’re a mission-driven group of deep learning researchers, software engineers, and proven drug developers. We believe close-knit, interdisciplinary collaboration is crucial for inventing important new technology and rapidly advancing optimal therapies. Through internal programs and selective partnerships with top pharmaceutical companies, we’re improving every stage of drug development, and ultimately transforming the lives of patients suffering from severe disorders.
Our Team
Evan Feinberg, Ph.D.
CEO, Co-founder
Evan received a degree in physics from Yale and a biophysics Ph.D. from Stanford working in Vijay Pande's lab. During his time at Stanford, he invented PotentialNet and consulted on deep learning for big pharma. Evan was also an early software engineer on the MoleculeNet and DeepChem open source projects.
Ben Sklaroff
VP Engineering, Co-founder
Ben received a degree in EECS from UC Berkeley, then joined Markforged when it was still in a garage. He led the software team there as Markforged became the 10th fastest growing company in North America.
James Schaeffer, Ph.D.
VP Business Strategy,
Co-founder
James spent more than 28 years at Merck, where he was Executive Director of Licensing, responsible for identification and evaluation of all West Coast licensing opportunities.
Peppi Prasit, Ph.D.
Acting CSO
Peppi co-founded Inception Sciences as well as Amira Pharmaceuticals. Previously, as a medicinal chemist at Merck he played a key role in the discovery and development of FDA-approved drugs Vioxx®, Arcoxia®, and Singulair®.
Nick Stock, Ph.D.
VP Medicinal Chemistry
Nick completed his chemistry degree and Ph.D. at Imperial College London. After a postdoc with Prof. Larry Overman at UC Irvine, he began his career with Merck in San Diego. Subsequently he was a founding team-member at both Amira Pharmaceuticals and Inception Sciences. He has published over 20 peer-reviewed papers and 34 granted US patents, encompassing several clinical-phase compounds.
Anders Papitto
Software Engineer
Anders received a degree in EECS from UC Berkeley. Since then, he has worked on relational database internals at MemSQL, and later on the PyTorch team at Facebook. 
Leonard Bell, M.D.
Chair of the Board of Directors
Dr. Bell was principal founder and CEO of Alexion Pharmaceuticals for 23 years, discovering and developing life-transforming therapies, and delivering them to patients in over 50 countries. In 2008, he accepted on behalf of Alexion the Prix Galien USA Award for Best Biotechnology Product, the industry's highest accolade for pharmaceutical R&D — equivalent to the Nobel Prize.
Investors